Resource Center

Bremelanotide is a melanocortin 3 and 4 receptor

agonist, taken as a subcutaneous injection before sexual activity.

• Flibanserin is classified as a centrally acting serotonergic agent.
• It is not a testosterone-based therapy, unlike some other treatments.
• The FDA approval was based on studies showing increased sexual desire in women.
• The medication can cause sleep disturbances, including somnolence.
• Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
• It is recommended to start treatment at least 4 weeks before expecting improvement.
• Discontinuation of the drug normally leads to the loss of effects.
• The drug's efficacy is modest compared to some male sexual dysfunction drugs.
• Initiation of therapy involves screening for contraindications.

[1,5,6] The US FDA approved flibanserin, supported by findings

Pharmacist tips for Addyi (flibanserin)

“I was in the room a decade ago when Addyi became the historic first for women’s sexual health, and I have been waiting for this moment ever since,” Rubin said. “So many of my postmenopausal patients have carried the weight of frustrating low sexual desire with no FDA-approved option to turn to. It’s a critical acknowledgment that their pleasure, their well-being, and their quality of life matter—and that science-backed care should be available to every woman, at every stage of her life.” International regulatory decisions preceded the US approval. In 2021, Health Canada authorized the use of flibanserin in postmenopausal women, a move that Sprout cited as an important step toward the current FDA action. With the expanded US indication, Addyi is now approved for women younger than 65 years, making it the first and only FDA-approved pharmacologic therapy for HSDD across this broader age range.

What is this drug used for?

Sprout Pharmaceuticals stated that Addyi has been prescribed by more than 30,000 US health care professionals to date. The company emphasized that appropriate patient selection and counseling remain essential and that patients should consult with their physicians to determine whether treatment is appropriate. Mary Claire Haver, MD, an obstetrician-gynecologist and menopause specialist, also emphasized the broader clinical context of the approval. “Menopause does not mark the end of a woman’s sexuality, but for too long, medicine has treated it that way,” Haver said. “This FDA approval is a long-overdue recognition that postmenopausal women deserve evidence-based treatment options for low sexual desire.

Brand Names: US

Expanding Addyi’s approval is historic in validating women’s experiences and ensuring that millions of women suffering have real choices when it comes to their sexual health.” Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in postmenopausal women. aDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh bDepartment of Endocrinology, North East Medical College and Hospital, Sylhet, Bangladesh cDepartment of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh dDepartment of Gyne & Obs, Khaliajuri Upazila Health Complex, Netrokona, Bangladesh eDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India fDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh gDepartment of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India. Received: 19 March 2024 / Received in final form: 23 May 2024 / Accepted: 24 May 2024 The authors have no funding and conflicts of interest to disclose. All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Supplemental Digital Content is available for this article. from 3 randomized placebo-controlled trials

involving premenopausal women with HSDD.

Before using flibanserin

Female sexual dysfunction (FSD) is common, even more common than male sexual dysfunction. There is limited data on the incidence and prevalence of FSD. [1] The fourth International Consultation on Sexual Medicine consensus statement asserts that, across a variety of assessment methods, the prevalence of women’s sexual complaints, regardless of age, is on the order of 40% to 50%. [2] Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual complaint in women. HSDD is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised, as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty.

Key Takeaways

[3] In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, HSDD has been replaced by Female Sexual Interest/Arousal Disorder, merging arousal and desire disorders. [4] It is estimated that about one in 10 women have HSDD. The prevalence varies with age; 8.9% of women ages 18 to 44, 12.3% ages 45 to 64, and 7.4% >65 years have HSDD. [5] Despite its high prevalence, effective pharmacotherapy for HSDD is still limited. Only two medications, flibanserin and bremelanotide, have been approved by the United States Food and Drug Administration (US FDA) for treating HSDD in premenopausal women. These trials demonstrated statistically

• Flibanserin should be discontinued if no benefit is observed after several weeks.
• The medication's influence on mental health conditions is still being studied.
• Flibanserin was recognized as a breakthrough therapy for female sexual desire issues.
• Its use is guided by strict medical protocols due to safety concerns.
• Women are encouraged to report any adverse effects during treatment.
• Continued research aims to improve treatment options for female sexual health.
• Flibanserin is one of a few FDA-approved drugs for Female Sexual Desire Disorder.
• Clinical improvements may include increased frequency of satisfying sexual events.
• The drug's use should be combined with counseling when appropriate.

significant enhancements in sexual

• Flibanserin, a serotonin receptor modulator, was initially investigated for depression.
• Its approval marked a historic moment in treating female sexual dysfunction.
• The medication's side effects necessitate careful patient education.
• Efficacy is often supported by patient-reported improvements in desire.
• It does not function as an aphrodisiac but affects brain chemistry.
• Flibanserin therapy requires adherence to dosing instructions.
• Women with low libido due to other health issues may not benefit from it.
• Its role is to complement behavioral or psychological therapy if needed.
• Research continues into better options for treating female hypoactive sexual desire.

desire, desire-related distress, and

The Big Pink Fight for the Little Pink Pill

The decision expands the drug’s original indication and represents the first FDA approval specifically extending pharmacologic treatment options for postmenopausal women with HSDD. HSDD is characterized by a persistent lack of sexual interest or desire that causes distress and is not better explained by another medical or psychiatric condition. It is considered the most common form of sexual dysfunction in women, with estimates suggesting that approximately 40% of women experience symptoms consistent with low sexual desire at some point in their lives. Despite its prevalence, treatment options have historically been limited, particularly for postmenopausal women. “This milestone reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized,” said Cindy Eckert, founder and CEO of Sprout Pharmaceuticals.

InChI key

“Over the years, we’ve pushed for the science to speak louder than the stigma—and today’s approval shows how far we’ve come. I want to congratulate the FDA for recognizing what millions of women have long deserved: equitable, science-backed care at every stage of life.” Addyi was initially approved by the FDA in 2015 for the treatment of HSDD in premenopausal women. The medication is a nonhormonal, centrally acting agent that modulates key neurotransmitters involved in sexual response. Since its original approval, its safety and efficacy profile has been evaluated in extensive clinical development programs, which Sprout described as the largest and most rigorous clinical trials conducted in women’s sexual health. The current approval follows the FDA’s decision earlier this year to grant priority review status to the expanded indication.

Hypoactive Sexual Desire Disorder

Priority review is reserved for therapies that may provide significant improvements in the treatment of serious conditions or address unmet medical needs. According to the company, the designation and subsequent approval reflect increasing regulatory attention to gaps in women’s health care. “This is a major shift in expanding awareness and access to treatment for HSDD—a condition that is both common and profoundly undertreated—and we’re grateful that the FDA has acknowledged the importance of closing this gap in women’s sexual health care,” Eckert added. Clinicians who specialize in sexual medicine and menopause care have described the expanded approval as an important step for patients who previously lacked FDA-approved treatment options. Rachel Rubin, MD, a urologist and sexual medicine specialist, highlighted the clinical implications for postmenopausal patients. the frequency of satisfying sexual events (SSE) when administered at a dosage of

Disorder of Sexual Interest and Desire, or of Arousal?

How to cite this article: Kamrul-Hasan ABM, Hannan MA, Alam MS, Aalpona FTZ, Nagendra L, Selim S, Dutta D. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis. Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh Sadar, Mymensingh 2200, Bangladesh (e-mail: [email protected]). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, buy super p force jelly transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING and SPECIAL PRECAUTIONS sections, call your doctor immediately:

Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs). This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively. RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases. The primary outcomes were the changes from baseline in satisfying sexual events (SSE) per month and sexual desire score per month measured using an electronic diary (eDiary). From 478 initially screened articles, data from 8 RCTs involving 7906 women with HSDD were analyzed.

How do I store and/or throw out this drug?

In premenopausal women, flibanserin 100 mg was superior to placebo in improving the number of SSE per month (mean difference, MD 0.69, 95% CI [0.39, 0.99]), eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (FSFI-d) score (MD 0.30, 95% CI [0.29, 0.31]), FSFI total score (MD 2.51, 95% CI [1.47, 3.55]), Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD −0.30, 95% CI [−0.31, −0.29]), and FSDS-R total score (MD −3.30, 95% CI [−3.37, −3.23]). Compared to placebo, a higher number of premenopausal women using flibanserin 100 mg achieved improvements in the Patient’s Global Impression of Improvement score (OR 1.93, 95% CI [1.58, 2.36], P < .00001) and responded positively at Patient Benefit Evaluation (PBE) (odds ratio, OR 1.76, 95% CI [1.34, 2.31], P < .0001). Postmenopausal women receiving flibanserin 100 mg also benefited in terms of the number of SSE per month, FSFI-d and total scores, FSDS-R Item 13 and total scores, and PBE response. Although flibanserin use was associated with higher risks of dizziness, fatigue, nausea, somnolence, and insomnia, these adverse events were mild in nature; the serious AEs and severe AEs were comparable between the flibanserin and placebo groups. While flibanserin has demonstrated efficacy in the treatment of HSDD in both pre- and postmenopausal women, its therapeutic advantages may be overshadowed by the higher likelihood of AEs. 100 mg (daily at bedtime) compared to a placebo.